Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary tenecteplase versus abciximab during primary PCI for anterior STEMI
2010-022725-16Phase 3Active
- Sponsor
- FRANCISCO JOSE MORALES PONCE
- Start
- Mar 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) comparing Intracoronary tenecteplase with Abciximab (2 arms). Primary endpoint: Final myocardial infarction size. Started Mar 2012; status: active.
02
Drugs
tenecteplaseabciximab
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2010-022725-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022725-16.